• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pulmatrix shares droop on growing losses in FY2016 earnings report

March 10, 2017 By Fink Densford

Shares in Pulmatrix (NSDQ:PULM) fell today after the medical device maker posted earnings that showed losses growing while revenue shrunk compared with the prior year.

The Lexington, Mass.-based company posted losses of $27.8 million, or $1.88 per share, on sales of $835,000 for the full year, with losses growing 6.4% while revenue shrunk 30.5% when compared with 2015.

On the upside, the company saw losses per share down 41.8% compared to the prior year.

“The company continues to advance its 2 iSperse-based product candidates and recently strengthened our balance sheet, with the closing of two registered direct offerings that brought in net proceeds of approximately $7.5 million. We expect pre-clinical data in the first half of 2017 on PUR1900 targeting fungal infections for severe asthma and cystic fibrosis patients and seek to secure a strategic partner(s) on PUR0200, a branded generic bronchodilator for COPD. As our product pipeline and iSperse technology continue to advance, we feel the Company is positioned for success as a leader in the treatment of respiratory diseases,” CEO Robert Clarke said in a press release.

Pulmatrix said it plans to continue to advance its current pipeline in 2017, with meetings slated with the FDA and EU regulatory bodies regarding the critical path for clinical development and approval of its PUR0200 branded generic bronchodilator for COPD.

The company said it will also work towards initial testing of its PUR1900 inhaled anti-fungal, initially targeted for patients with cystic fibrosis and severe asthma.

Shares have dropped 5.7% to $3.30 as of 3:49 p.m. EST.

Filed Under: Business/Financial News Tagged With: Pulmatrix Inc.

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS